| Company Name: | AVANIR Pharmaceuticals | | Ticker Symbol: | AVNR | | | WWW Address: | www.avanir.com |
| CEO: | Keith A. Katkin | | No. of Employees: | 225 |
| Common Issue Type: | CS | | Business Description: | Avanir Pharmaceuticals is a pharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders.
|
| | | Industry Information: | DRUGS - Drugs - Generic [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 4.57 |  -0.045 | 4.57 | 4.61 | 4.61 | 4.28 | 4.11 | 19265 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 663.1 | 145.1 | 1.99 | -0.45 | 0.00 | 0.0 | 0.0 | 4.34 - 2.07 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 4.26 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 663.1 | mil |
| Latest Shares Outstanding | 145.1 | mil |
| Earnings pS (EPS) | -0.45 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 183,445 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 99.1 | mil |
| Float as % of Shares Outstanding | 72.4 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 135.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 49.00 | % |
| Gross Profit Margin | 96.9 | % |
| EBITDA Margin | -87.2 | % |
| Pre-Tax Profit Margin | -95.4 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | -64.6 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -103.6 | % |
| Current Ratio | 2.6 | |
| Leverage Ratio (Assets/Equity) | 2.7 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.91 | |
| LT Debt/Total Capital | 40.0 | % |
| Working Capital pS | 0.35 | $ |
| Cash pS | 0.47 | $ |
| Book-Value pS | 0.22 | $ |
| Tangible Book-Value pS | 0.22 | $ |
| Cash Flow pS | -0.37 | $ |
| Free Cash Flow pS | -0.34 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 19.26 | |
| Price/Tangible Book Ratio | 19.26 | |
| Price/Cash Flow | -11.4 | |
| Price/Free Cash Flow | -12.5 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 13.0 | 113 | 32,592 | 147,039 |
| 4 Weeks | 4.34 | 3.15 | 3.32 | 28.3 | 131 | 22,702 | 408,629 |
| 13 Weeks | 4.34 | 2.60 | 3.06 | 39.2 | 133 | 15,113 | 937,033 |
| 26 Weeks | 4.34 | 2.49 | 2.53 | 68.4 | 145 | 13,877 | 1,706,844 |
| 52 Weeks | 4.34 | 2.07 | 3.05 | 39.7 | 115 | 13,032 | 3,231,992 |
| YTD | 4.34 | 2.60 | - | 62.8 | 142 | 14,295 | 1,615,357 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 4.10 | 3.83 | 3.28 | 2.98 | 3.02 | 1.99 | 1.25 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 45.15 | 44.1 | 142.27 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 224.04 |
| R&D | 11.72 | NA | 20.78 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 97.3 | 73.6 | 293.2 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.04 | 0.01 | 0.06 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 70.45 |
| Current Ratio | 4.0 |
| Quick Ratio (Acid Test) | 3.8 |
| Liquidity Ratio (Cash) | 3.49 |
| Receivables Turnover | 8.9 |
| Average Collection Period | 40 |
| Working Capital/Equity | 164.5 |
| Working Capital pS | 0.44 |
| Cash-Flow pS | -0.43 |
| Free Cash-Flow pS | -0.43 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 5.68 |
| Financial Leverage Ratio (Assets/Equity) | 2.3 |
| Debt Ratio | 57.2 |
| Total Debt/Equity (Gearing Ratio) | 0.78 |
| LT Debt/Equity | 0.72 |
| LT Debt/Capital Invested | 45.4 |
| LT Debt/Total Liabilities | 54.3 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 2.11 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 5.18 |
| Tobin's Q Ratio | 7.19 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -10.38 |
| Enterprise Value (EV)/Free Cash Flow | -10.07 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 19.26 |
| Price/Book Ratio - LTM | 19.26 |
| Price/Cash Flow Ratio | -11.4 |
| Price/Free Cash Flow Ratio - LTM | -12.5 |
| Price/Sales Ratio | 10.65 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.20 |
| Current Liabilities pS | 0.15 |
| Tangible Book Value pS - LTM | 0.22 |
| Book Value pS - LTM | 0.22 |
| Capital Invested pS | 0.44 |
| Cash pS - LTM | 0.47 |
| Cash Flow pS - LTM | -0.37 |
| Free Cash Flow pS - LTM | -0.34 |
| Earnings pS (EPS) | -0.45 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -141.66 |
| Free Cash Flow Margin 5YEAR AVG | -450.41 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 1.12 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.65 |
| Return on Capital Invested (ROCI) | -94.0 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -88.1 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | -69.5 |
| Return on Assets (ROA) - 5YEAR AVRG. | -62.7 |
| Gross Profit Margin | 96.9 |
| Gross Profit Margin - 5YEAR AVRG. | 96.9 |
| EBITDA Margin - LTM | -87.2 |
| EBIT Margin - LTM | -89.4 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | -0.0 |
| Effective Tax Rate - 5YEAR AVRG. | -0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 163 |
| Revenue per Employee | 183,445 |
| Net Income per Employee | -265,528 |
| Average Collection Period | 63 |
| Receivables Turnover | 8.9 |
| Day's Inventory Turnover Ratio | 100 |
| Inventory Turnover | 3.6 |
| Inventory/Sales | 1.0 |
| Accounts Payble/Sales | 12.34 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | 0.68 |
| Fixed Assets Turnover | 8.10 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 0.59 |
| Revenue per $ Plant | 22.82 |
| Revenue per $ Common Equity | 1.12 |
| Revenue per $ Capital Invested | 0.65 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 180.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 254.0 |
| Research & Devlopment (R&D) as % of Revenue | 55.9 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 55.9 |
|
|  
|
| |
 |  |
